HHLA2 and hepatocellular carcinoma: HHLA2-low patients had lower estimated IC50 values for imatinib (Figure 7A) and sorafenib (Figure 7B), indicating that HHLA2-low HCC patients were more resistant to sorafenib or imatinib treatment.